Thryv Therapeutics

We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.

Without Limits.

Announcement: Thryv Therapeutics to Participate at the 2024 Jefferies Global Healthcare Conference Read More.

Our Focus:

Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).

Breaking Barriers:

Press Releases

Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer

Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025

Thryv Therapeutics Announces Participation in Four Major Upcoming Investor Conferences

Thryv Therapeutics Announces Participation in Four Major Upcoming Investor Conferences

Thryv Therapeutics to Sponsor and Participate in the 2024 International SADS Foundation Family Conference in Chicago

Thryv Therapeutics to Sponsor and Participate in the 2024 International SADS Foundation Family Conference in Chicago

Thryv Therapeutics Announces Four Abstracts Accepted for AHA 2024 Annual Scientific Sessions

Thryv Therapeutics Announces Four Abstracts Accepted for AHA 2024 Annual Scientific Sessions

Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment

Thryv Therapeutics to Participate in Fireside Chat During 2024 RBC Capital Markets Biotechnology Private Company Virtual Conference

Thryv Therapeutics to Participate in Fireside Chat During 2024 RBC Capital Markets Biotechnology Private Company Virtual Conference

Thryv Therapeutics to Participate at the 2024 Jefferies Global Healthcare Conference

Thryv Therapeutics to Participate at the 2024 Jefferies Global Healthcare Conference

Thryv Therapeutics to Present Preclinical Data of SGK1 Inhibition in Models of Drug-Induced QT Prolongation at the 2024 Heart Rhythm Society Meeting

Thryv Therapeutics to Present Preclinical Data of SGK1 Inhibition in Models of Drug-Induced QT Prolongation at the 2024 Heart Rhythm Society Meeting

Thryv Therapeutics to Participate at the Piper Sandler Spring Biopharma Symposium

Thryv Therapeutics to Participate at the Piper Sandler Spring Biopharma Symposium

Thryv Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Thryv Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Thryv Therapeutics to Present Results of Wave I Part 1 Clinical Study at American College of Cardiology Conference in Atlanta, Georgia on April 7th, 2024

Thryv Therapeutics to Present Results of Wave I Part 1 Clinical Study at American College of Cardiology Conference in Atlanta, Georgia on April 7th, 2024

Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

2023 Year End Report

2023 Year End Report

Thryv Therapeutics to Present at the 2023 RBC Capital Markets Private Company Conference

Thryv Therapeutics to Present at the 2023 RBC Capital Markets Private Company Conference

Thryv Therapeutics’ CEO, Paul Truex, to Present at Piper Sandler’s 35th Annual Healthcare Conference

Thryv Therapeutics’ CEO, Paul Truex, to Present at Piper Sandler’s 35th Annual Healthcare Conference

Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions

Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT Induced by Dofetilide.

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT Induced by Dofetilide.

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec

Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec

Isla Hutton

Long QT Type 3

We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome - In memory of Isla.

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Together We Thryv

The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.

Together we share a vision to transform the lives of people with life-threatening conditions.

Amplitude Ventures (Copy)

The Fonds de solidarité FTQ (Copy)

Lumira Ventures (Copy)

Amzak Health (Copy)

Alexandria Venture Investments (Copy)

adMare BioInnovations (Copy)

Follow our journey

📣 Our inaugural "Ask Thryv Live" webinar was a hit! ✨ We had an hour-long deep dive on all things Thryv, from updates on our Long QT Syndrome & Heart Failure programs to exciting new research on SGK1 and fibrosis. With 70 attendees and

📣 Thryv is pleased to announce our poster presentation of SGK1 inhibition in models of Drug-Induced QT prolongation at the 2024 Heart Rhythm Society meeting in Boston, MA. This presentation will take place on Friday, May 17th, from 10:30 a.m. to 12:

📣 Don't forget to register for Ask Thryv Live! ✨ We are going live next Tuesday, May 7th from 11:30 a.m. to 12:30 p.m. 💚 Hear the latest updates on our Long QT program and updated progress for our new therapy for atrial fibrillation and heart failu

📣 Successful weekend at #ACC2024 for Thryv! 🎉 We were thrilled to showcase our groundbreaking poster “SGK1 inhibitor LQT-1213 significantly attenuates dofetilide-induced QT prolongation in humans: Results of the WAVE I Clinical Study”.

📣 Thryv Therapeutics is pleased to announce that it will be hosting investor meetings at the Piper Sandler Spring Biopharma Symposium on Tuesday, April 16, 2024, at the Encore Boston Harbor. ✨ Read the full press release at the link in bio!

📣 Thryv Therapeutics is pleased to announce its selection as a featured presenter at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The virtual presentation will take place on Tuesday, April 16th, 2024, from 3:00 p.m. to 3:30 p.m. E

Captivated by the cosmic spectacle! 🌞🌑 The Thryv team immersed in yesterday's total solar eclipse. Huge thanks to Doug for hosting and to Marc & Shannon for the awesome photos! 🌟 #SolarEclipse #TeamBonding

📣Thryv Therapeutics will participate in a virtual fireside chat at the Piper Sandler Virtual Cardio Day on April 10, 2024 at 12 p.m. ET. Participants will include leadership from presenting companies and highlights from presentations at the American

📣Thryv Therapeutics is pleased to announce the presentation of its poster: SGK1 inhibitor LQT-1213 significantly attenuates dofetilide-induced QT prolongation in humans: Results of the WAVE I Clinical Study at the American College of Cardiology Conf

Thryv Therapeutics will be attending the American College of Cardiology Conference in Atlanta from April 6th-8th. We are looking to meet Cardiologists and Electrophysiologists who treat Long QT Syndrome and/or atrial fibrillation. If you are interest

Thryv Therapeutics will be attending the American College of Cardiology Conference in Atlanta from April 6th-8th. We are looking to meet with Cardiologists who treat Heart Failure. If you are interested in learning more, please reach out to admin@thr

📣 Happy International Women's Day! Today we celebrate the incredible women who inspire us everyday. A special shoutout goes out to the hardworking women at Thryv Therapeutics. 💚

✨Debra Odink - President & Chief Development Officer
✨Aidan McNei

Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Evercore ISI 2024 Emerging Biotech Conference that is taking place virtually on February 28th and 29th, 2024. Thryv’s virtual presentation will be on Februar

This week is Heart Failure Awareness Week! Did you know that Thryv Therapeutics is currently conducting preclinical studies in animal models of Heart Failure with Preserved Ejection Fraction (HFpEF) to evaluate the effect of our SGK1 inhibitors? Lear

Celebrating our brilliant female team members at Thryv Therapeutics on #WomenInSTEMDay. 👩&zwj;🔬💡 Their passion, expertise, and dedication inspire us all to reach new heights in the world of science and technology. #ThryvWomenInSTEM #BeRelentless #

World Heart Month kicks off in vibrant red fashion with National Wear Red Day! The Thryv team is proudly sporting red today to show our unwavering support for #HeartHealth. Join us in spreading awareness and post your #WearRedDay outfits! #LongQTSynd

February marks World Heart Month, urging everyone to prioritize their cardiovascular health. At Thryv, our commitment is unwavering as we strive to advance treatments for heart arrhythmias, including Long QT Syndrome and atrial fibrillation. Explore

Contact Spaulding Clinical for more information about our clinical study for people with Long QT Syndrome types 2 and 3 💚

#longqtsyndrome #lqts #clinicalstudy #heartarrhythmia